Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
As of close of business last night, NeuroOne Medical Technologies Corp’s stock clocked out at $0.93, up 0.10% from its previous closing price of $0.93. In other words, the price has increased by $0.10 from its previous closing price. On the day, 0.68 million shares were traded. NMTC stock price reached its highest trading level at $0.96 during the session, while it also had its lowest trading level at $0.9265.
Ratios:
To gain a deeper understanding of NMTC’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.80 and its Current Ratio is at 7.13. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of . The stock’s future direction. In the most recent recommendation for this company, Ladenburg Thalmann on May 05, 2025, initiated with a Buy rating and assigned the stock a target price of $1.45.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 05 ’25 when Christianson Mark sold 30,000 shares for $0.74 per share. The transaction valued at 22,203 led to the insider holds 231,238 shares of the business.
Christianson Mark bought 30,000 shares of NMTC for $24,210 on Aug 20 ’25. On Jun 04 ’25, another insider, Christianson Mark, who serves as the Business Development Director of the company, sold 10,000 shares for $0.58 each. As a result, the insider received 5,804 and left with 261,491 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NMTC now has a Market Capitalization of 46544552 and an Enterprise Value of 38800588. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.83 while its Price-to-Book (P/B) ratio in mrq is 5.67. Its current Enterprise Value per Revenue stands at 5.853 whereas that against EBITDA is -7.171.
Stock Price History:
The Beta on a monthly basis for NMTC is 0.66, which has changed by -0.0633803 over the last 52 weeks, in comparison to a change of 0.1675967 over the same period for the S&P500. Over the past 52 weeks, NMTC has reached a high of $1.39, while it has fallen to a 52-week low of $0.40. The 50-Day Moving Average of the stock is 13.63%, while the 200-Day Moving Average is calculated to be 14.03%.
Shares Statistics:
It appears that NMTC traded 280.29K shares on average per day over the past three months and 436130 shares per day over the past ten days. A total of 49.82M shares are outstanding, with a floating share count of 44.06M. Insiders hold about 11.88% of the company’s shares, while institutions hold 42.03% stake in the company. Shares short for NMTC as of 1756425600 were 185564 with a Short Ratio of 0.66, compared to 1753920000 on 150101. Therefore, it implies a Short% of Shares Outstanding of 185564 and a Short% of Float of 0.38.
Earnings Estimates
NeuroOne Medical Technologies Corp (NMTC) is presently subject to a detailed evaluation by 2 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.04, with high estimates of -$0.03 and low estimates of -$0.04.
Analysts are recommending an EPS of between -$0.1 and -$0.13 for the fiscal current year, implying an average EPS of -$0.12. EPS for the following year is -$0.14, with 2.0 analysts recommending between -$0.14 and -$0.15.
Revenue Estimates
For the next quarter, 2 analysts are estimating revenue of $2.69M. There is a high estimate of $2.98M for the next quarter, whereas the lowest estimate is $2.4M.
Based on 2 analysts’ estimates, the company’s revenue will be $11.26M in the next fiscal year. The high estimate is $12.4M and the low estimate is $10.11M.
